News of Note—Merck’s Zostavax, GeoVax and more

non
In this week's news of note, an appeals court upheld a lower court's decision to throw out a Zostavax injury lawsuit. (Pixabay)

Here is some other vaccine news of note for the week.

> A U.S. Circuit Court of Appeals affirmed a lower court's decision to throw out a Zostavax injury lawsuit against Merck due to the statute of limitations. Court opinion (PDF)

> GeoVax nabbed $300,000 from the NIH’s National Institute of Allergy and Infectious Diseases to support a phase 1 study of its Lassa fever vaccine program. Release

> The University of Washington’s Institute for Protein Design won a $11.3 million grant from the Open Philanthropy Project; about half of it will go toward the development of a universal flu vaccine. GeekWire article

> Using education campaigns to change people’s minds about vaccines is less effective than using behavioral nudges, a new study published in Psychological Science in the Public Interest found. Release